OUTCOME OF BOARD MEETING
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Beryl Drugs Ltd met on 30 May 2025 and approved the audited financial results for the quarter and year ended 31 March 2025, along with the audited Balance Sheet, Profit & Loss statement, and Cash Flow statement. The board also noted the statutory auditor's report for FY 2024-25 and approved a related party transaction. Additionally, Abhay Bhandari & Associates, Chartered Accountants, was appointed as Internal Auditor for FY 2025-26, and Mr. Sudhir Sethi was authorised as the signing authority for tender-related documents for the year.
Routine annual results approval with a related party transaction flagged for shareholder attention; investors should review the FY25 results and the nature of the related party transaction for any governance concerns.